← All trials
NCT05029297
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 4, 2010
- Primary completion
- Oct 23, 2018
- Completion date
- Oct 23, 2018
- First posted
- Aug 31, 2021
- Last posted
- Sep 14, 2021
- Enrollment
- 161
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Arafarma Group, S.A.Lead sponsor
- Fundación Teófilo Hernando, SpainCollaborator
- Universidad Autonoma de MadridOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.